Company Overview

We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products and a portfolio of central nervous system, or CNS, product candidates. Our immuno-oncology portfolio is based off a proprietary technology platform consisting of single-chain bi-, tri- and tetra-specific scFv constructs, combined with proprietary antibody-drug linkers and drug payloads. Our CNS portfolio consists of innovative reformulations and/or repurposing of existing therapies that are covered by issued or filed composition of matter patents.